Why Oklo Stock Traded Lower on Wednesday

Oklo shares slid intraday (down about 5.4% early and roughly 2.5% by mid‑afternoon) after a more than 370% YTD rally and a pullback from October highs of $193.84; the stock trades around $101. Analysts are divided: Goldman Sachs’ Brian Lee reiterated a neutral rating with a $106 target (implying ~5% upside), while Seaport Global raised its target to $150 (~50% upside) after Oklo said it is evaluating plutonium as a fuel. Oklo is developing fast‑fission Aurora reactors that can run on uranium and recycled fuel, has a $2 billion partnership with newcleo to build U.S. fuel‑fabrication capacity to repurpose surplus plutonium, and is working on multiple DOE projects—factors that could confer a competitive edge but leave valuation and execution risk driving divergent analyst views and continued stock volatility.

Analysis

Oklo shares have slipped intraday — down about 5.4% early and roughly 2.5% by mid‑afternoon — trading near $101 after a more than 370% YTD rally and a peak of $193.84 in October, indicating significant recent profit‑taking. Goldman Sachs analyst Brian Lee met management on Dec. 9 and reiterated a neutral rating with a $106 price target, implying roughly 5% upside from the current price, while Seaport Global raised its target to $150 (roughly 50% upside) following Oklo's disclosure that it is evaluating plutonium as a reactor fuel. Oklo is developing fast‑fission Aurora reactors capable of using uranium and recycled fuel, has a $2 billion partnership with newcleo to build U.S. fuel‑fabrication capacity to repurpose surplus plutonium, and is engaged on multiple DOE projects — operational and regulatory milestones from these initiatives are the primary value drivers. The mixed analyst views and the company’s high prior run‑up leave valuation, execution, and regulatory acceptance of plutonium‑based fuel as the main near‑term risks; sentiment reads as cautious and market‑impact is modest but likely to sustain elevated volatility around catalyst announcements.

Key Decisions for Investors

• If you are a long‑term believer in advanced nuclear, consider accumulating incrementally on material weakness while keeping position sizes modest given execution and regulatory risk
• Monitor hard catalysts — regulatory approvals for plutonium fuel use, progress on the newcleo $2 billion fabrication program, and DOE project milestones — and reassess positioning if timelines or approvals slip
• Given the wide analyst price‑target dispersion and recent profit‑taking after a 370% run, consider trimming exposure on rallies or implementing downside protection until clearer execution evidence emerges